Sickle cell pain: Biology, etiology, and treatment

Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Second Edition

Volumn , Issue , 2009, Pages 497-524

  Ballas, Samir K ^a   Eckman, James R ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859913596     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511596582.028     Document Type: Chapter

References (254)

1. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325: 11-16.
2. Treadwell M, Gil KM. Psychosocial aspects. In: Embury S, Hebbel R, Mohandas N, Steinberg M, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press, Ltd.; 1994:517-529.
3. Shapiro BS, Dinges DF, Orne EC, et al. Home management of sickle cell-related pain in children and adolescents: natural history and impact on school attendance. Pain. 1995;61:139-144.
4. Walco GA, Dampier CD. Pain in children and adolescents with sickle cell disease: a descriptive study. J Pediatr Psychol. 1990;15:643-658.
5. Diggs LW. Sickle cell crisis. Am J Clin Pathol. 1965;44:1-19.
6. Konotey-Ahulu FI. The sickle cell diseases. Clinical manifestations including the "sickle crisis." Arch Intern Med. 1974;133:611-619.
7. Serjeant GR, Ceulaer CD, Lethbridge R, Morris J, Singhal A, Thomas PW. The painful crisis of homozygous sickle cell disease: clinical features. Br J Haematol. 1994;87:586-591.
8. Akinola NO, Stevens SM, Franklin IM, Nash GB, Stuart J. Subclinical ischaemic episodes during the steady state of sickle cell anaemia. J Clin Pathol. 1992;45:902-906.
9. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood. 1992;79:2154-2163.
10. Beyer JE, Simmons LE, Woods GM, Woods PM. A chronology of pain and comfort in children with sickle cell disease. Arch Pediatr AdolescMed. 1999;153:913-920.
11. Davies SC. The hospital management of patients with sickle cell disease. Haematologica. 1990;75 Suppl 5:96-106.
12. Feldman F, Zwass A, Staron RB, Haramati N. MRI of soft tissue abnormalities: a primary cause of sickle cell crisis. Skeletal Radiol. 1993;22:501-506.
13. Mankad VN, Williams JP, Harpen MD, et al. Magnetic resonance imaging of bone marrow in sickle cell disease: clinical, hematologic, and pathologic correlations. Blood. 1990;75:274-283.
14. Mankad VN, Yang YM, Williams JP, Brogdon BG. Magnetic resonance imaging of bone marrowin sickle cell patients. Am J Pediatr Hematol Oncol. 1988;10:344-347.
15. Bunn HF. Pathogenesis and treatment of sickle cell disease. NEngl J Med. 1997;337:762-769.
16. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340:1021-1030.
17. Embury SH, Hebbel RP, Steinberg MH, Mohandas N. Pathogenesis of vasoocclusion. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press, Ltd.; 1994:311-326.
18. Ballas SK, Mohandas N. Sickle red cell microrheology and sickle blood rheology.Microcirculation. 2004;11:209-225.
19. Chiang EY, Frenette PS. Sickle cell vasoocclusion. Hematol Oncol Clin North Am. 2005;19:771-784.
20. Frenette PS. Sickle cell vasoocclusion: heterotypic, multicellular aggregations driven by leukocyte adhesion. Microcirculation. 2004;11:167-177.
21. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest. 2007;117: 850-858.
22. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11:129-151.
23. Benjamin LJ. Nature and treatment of the acute painful episode in sickle cell disease. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. New York: Cambridge University Press; 2001:671-710.
24. Embury S, Hebbel R, Mohandas N, Steinberg M. Sickle cell disease. Basic Principles and Clinical Picture. New York: Raven Press, Ltd.; 1994.
25. Serjeant GR. Sickle CellDisease. 3rd ed.New York: OxfordUniversity Press; 2001.
26. Boros L, Thomas C, Weiner WJ. Large cerebral vessel disease in sickle cell anaemia. J Neurol Neurosurg Psychiatry. 1976;39:1236-1239.
27. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am JMed. 1978;65:461-471.
28. Powars DR. Sickle cell anemia and major organ failure. Hemoglobin. 1990;14:573-598.
29. Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood. 1991;77:214-237.
30. Francis RB, Jr., Johnson CS. Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood. 1991;77:1405-1414.
31. Fields HL. Pain. New York:McGraw-Hill; 1987.
32. Katz N, Ferrante FM. Nociception. In: Ferrante FM, Vade-Boncoeur TR, eds. Post Operative Pain Management. New York: Churchill Livingstone; 1993:17-67.
33. Kaul DK. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411-420.
34. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337-338.
35. Cousins MJ, John J. Bonica distinguished lecture. Acute pain and the injury response: immediate and prolonged effects. Reg Anesth. 1989;14:162-179.
36. Cousins MJ. Acute post operative pain. In: Wall PD, Melzack R, eds. Textbook of Pain. New York: Churchill Livingstone; 1994:357-385.
37. McMahon SB, Koltzeninburg M, eds. In: Wall and Melzack's Textbook of Pain. 5th ed. New York: Churchill Livingstone; 2006.
38. Loeser JD, Butler SH, Chapman CR, Turk DC, eds. Bonica's Management of Pain. 3rd ed. Philadelphia: Lippincott Williams &Wilkins; 2001.
39. Ballas SK. The neurobiology and treatment of pain in sickle cell disease. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Scientific Principles and Clinical Practice. New York: Raven Press; 1994:745-772.
40. Ballas SK. Sickle cell disease. In: Rakel RE, ed. Conn's Current Therapy. Philadelphia: WB Saunders; 1995:318-327.
41. Meyer RA, Ringkamp M, Campbell JN, Raja SN. Peripheral mechanisms of cutaneous nociception. In: McMahon SB, Koltzeninburg M, eds. Wall and Melzack's Textbook of Pain. 5th ed. New York: Churchill Livingston; 2006:16.
42. Dunn MJ, Hood VL. Prostaglandins and the kidney. Am J Physiol. 1977;233:169-184.
43. Dyck PJ, ed. Peripheral Neuropathy. Philadelphia: Saunders; 1975.
44. Ballas SK. Sickle cell pain. Progress in Pain Research andManagement. Seattle: IASP Press; 1998.
45. Melzack R. Pain questionnaire: major properties and scoring. Pain. 1975;1:277-299.
46. Wall PD, Melzack R, eds. Textbook of Pain. 3rd ed. New York: Churchill Livingstone; 1994.
47. Anderson P, Morris R, Amaral D, et al. The Hippocampus Book. New York: Oxford University Press; 2007.
48. Choi DS, Choi DY, Whittington RA, Nedeljkovic SS. Sudden amnesia resulting in pain relief: the relationship between memory and pain. Pain. 2007;132:206-210.
49. Basbaum AI. The generation and control of pain. In: Rosenberg RN, Grossman RG, Schochet Jr SS, Heinz ER, Willis WD, eds. The ClinicalNeurosciences, Neurobiology. NewYork: Churchill Livingstone; 1983:V301-V24.
50. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7:309-338.
51. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79:17-25.
52. Vichinsky EP, Johnson R, Lubin BH. Multidisciplinary approach to pain management in sickle cell disease. Am J Pediatr Hematol Oncol. 1982;4:328-333.
53. Bonds DR. Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype. Blood Rev. 2005;19:99-110.
54. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol. 2005;129:465-481.
55. Powars DR. Sickle cell anemia: beta s-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol. 1991;28:202-208.
56. Udezue E, Girshab AM. Differences between males and females in adult sickle cell pain crisis in eastern Saudi Arabia. Ann Saudi Med. 2004;24:179-182.
57. Ballas SK, Larner J, Smith ED, Surrey S, Schwartz E, Rappaport EF. Rheologic predictors of the severity of the painful sickle cell crisis. Blood. 1988;72:1216-1223.
58. Lande WM, Andrews DL, Clark MR, et al. The incidence of painful crisis in homozygous sickle cell disease: correlation with red cell deformability. Blood. 1988;72:2056-2059.
59. Baum KF, Dunn DT, Maude GH, Serjeant GR. The painful crisis of homozygous sickle cell disease. A study of the risk factors. Arch InternMed. 1987;147:1231-1234.
60. Taylor JG IV, Nolan VG, Mendelsohn L, Kato GJ, Gladwi, MT, Steinberg MH. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain PLoS One. 2008; 3(5)e 2095.
61. Hargrave DR, Wade A, Evans JP, Hewes DK, Kirkham FJ. Nocturnal oxygen saturation and painful sickle cell crises in children. Blood. 2003;101:846-848.
62. Schall JI, Zemel BS, Kawchak DA, Ohene-Frempong K, Stallings VA. Vitamin A status, hospitalizations, and other outcomes in young children with sickle cell disease. J Pediatr. 2004;145:99-106.
63. Gil KM, Carson JW, Porter LS, Scipio C, Bediako SM, Orringer E. Daily mood and stress predict pain, health care use, and work activity in African American adults with sickle-cell disease. Health Psychol. 2004;23:267-274.
64. Amjad H, Bannerman RM, Judisch JM. Letter: Sickling pain and season. BrMed J. 1974;2:54.
65. Ibrahim AS. Relationship between meteorological changes and occurrence of painful sickle cell crises in Kuwait. Trans R Soc TropMed Hyg. 1980;74:159-161.
66. Redwood AM, Williams EM, Desal P, Serjeant GR. Climate and painful crisis of sickle-cell disease in Jamaica. Br Med J. 1976;1:66-68.
67. Kehinde MO, Marsh JC, Marsh GW. Sickle cell disease in North London. Br J Haematol. 1987;66:543-547.
68. Seeler RA. Non-seasonality of sickle-cell crisis. Lancet. 1973;2:743.
69. Slovis CM, Talley JD, Pitts RB. Non relationship of climatologic factors and painful sickle cell anemia crisis. J Chronic Dis. 1986;39:121-126.
70. Smith WR, Coyne P, Smith VS, Mercier B. Temperature changes, temperature extremes, and their relationship to emergency department visits and hospitalizations for sickle cell crisis. Pain Manage Nurs. 2003;4:106-111.
71. Jones S, Duncan ER, Thomas N, et al.Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. Br J Haematol. 2005;131:530-533.
72. Yallop D, Duncan ER, Norris E, et al. The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment. Br J Haematol. 2007;136:844-848.
73. Nolan VG, Zhang Y, Lash T, Sebastiani P, Steinberg MH. Association of wind speed and the occurrence of sickle cell acute painful episodes: results of a case-crossover study. Br J Haematol. 2008; 143(3) 433-438.
74. Resar LM, Oski FA. Cold water exposure and vaso-occlusive crises in sickle cell anemia. J Pediatr. 1991;118:407-409.
75. Dampier C, Ely E, Brodecki D, O'Neal P. Home management of pain in sickle cell disease: a daily diary study in children and adolescents. J Pediatr Hematol Oncol. 2002;24:643-647.
76. Anie KA, Steptoe A, Bevan DH. Sickle cell disease: pain, coping and quality of life in a study of adults in the UK. Br JHealth Psychol. 2002;7:331-344.
77. FuggleP, ShandPA, Gill LJ, DaviesSC. Pain, qualityof life, and coping in sickle cell disease. Arch Dis Child. 1996;75:199-203.
78. Porter LS, Gil KM, Sedway JA, Ready J, Workman E, Thompson RJ, Jr. Pain and stress in sickle cell disease: an analysis of daily pain records. Int J BehavMed. 1998;5:185-203.
79. Westerman MP, Bailey K, Freels S, Schlegel R, Williamson P. Assessment of painful episode frequency in sickle-cell disease. Am J Hematol. 1997;54:183-188.
80. SmithWR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148:94-101.
81. Akinola NO, Stevens SM, Franklin IM, Nash GB, Stuart J. Rheological changes in the prodromal and established phases of sickle cell vaso-occlusive crisis. Br J Haematol. 1992;81:598-602.
82. Ballas SK. The sickle cell painful crisis in adults: phases and objective signs. Hemoglobin. 1995;19:323-333.
83. Jacob E, Beyer JE, Miaskowski C, Savedra M, Treadwell M, Styles L. Are there phases to the vaso-occlusive painful episode in sickle cell disease? J Pain Symptom Manage. 2005; 29:392-400.
84. Neuman HN, Diggs LW, Schlenker FS, et al. Increased urinary porphyrin excretion in sickle cell crises. Proc Soc Exp BiolMed. 1966;123:1-4.
85. Schumaker HR. Rheumatological manifestation of sickle disease and other haemoglobinopathies. Clin Rheum Dis. 1975;1:37-52.
86. Schumacher HR, Andrews R, McLaughlin G. Arthropathy in sickle-cell disease. Ann InternMed. 1973;78:203-211.
87. Brugsch HG, Gill D. Polyarthritis in sickle cell anemia.NEngl J Med. 1944;231:291-292.
88. Espinoza LR, Spilberg I, Osterland CK. Joint manifestations of sickle cell disease.Medicine (Baltimore). 1974;53:295-305.
89. Miller RL, Webster ME, Melmon KL. Interaction of leukocytes and endotoxin with the plasmin and kinin systems. Eur J Pharmacol. 1975;33:53-60.
90. Dorwart BB, Gabuzda TG. Symmetric myositis and fasciitis: a complication of sickle cell anemia during vasoocclusion. J Rheumatol. 1985;12:590-595.
91. Valeriano-Marcet J, Kerr LD. Myonecrosis and myofibrosis as complications of sickle cell anemia. Ann Intern Med. 1991;115:99-101.
92. Schumacher HR, Jr., Murray WM, Dalinka MK. Acute muscle injury complicating sickle cell crisis. Semin Arthritis Rheum. 1990;19:243-7.
93. Walker BK, Brownstein PK, Burka ER, Ballas SK. Urinary retention in sickle cell syndromes. Urology. 1980;16:33-35.
94. Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion. 2006;46:105-110.
95. Buchanan GR, Glader BE. Leukocyte counts in children with sickle cell disease. Comparative values in the steady state, vaso-occlusive crisis, and bacterial infection. Am J Dis Child. 1978;132:396-398.
96. Billett HH, Nagel RL, Fabry ME. Evolution of laboratory parameters during sickle cell painful crisis: evidence compatible with dense red cell sequestration without thrombosis. Am J Med Sci. 1988;296:293-298.
97. Green D, Kwaan HRG. Impaired fibrinolysis in sickle cell disease. Relation to crisis and infection. Thromb Diath Haemorrh. 1970;24:10-16.
98. Haut MJ, Cowan DH, Harris JW. Platelet function and survival in sickle cell disease. J Lab ClinMed. 1973;82:44-53.
99. Kenny MW, George AJ, Stuart J. Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol. 1980;33:622-625.
100. Billett HH, Fabry ME, Nagel RL. Hemoglobin distribution width: a rapid assessment of dense red cells in the steady state and during painful crisis in sickle cell anemia. J Lab Clin Med. 1988;112:339-344.
101. Van Der Sar A. The sudden rise in platelets and reticulocytes in sickle cell crises. Trop GeogrMed. 1970;22:30-40.
102. Gordon PA, Breeze GR, Mann JR, Stuart J. Coagulation fibrinolysis in sickle-cell disease. J Clin Pathol. 1974;27:485-489.
103. Alkjaersig N, Fletcher A, Joist H, Chaplin H, Jr. Hemostatic alterations accompanying sickle cell pain crises. J Lab Clin Med. 1976;88:440-449.
104. Jacob E, Miaskowski C, Savedra M, Beyer JE, Treadwell M, Styles L. Changes in intensity, location, and quality of vasoocclusive pain in children with sickle cell disease. Pain. 2003;102:187-193.
105. Jacob E, Mueller BU. Pain experience of children with sickle cell disease who had prolonged hospitalizations for acute painful episodes. Pain Med. 2008;9:13-21.
106. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab ClinMed. 2001;137:398-407.
107. Frei-Jones MJ, DeBaun MR. Hospital readmission within 30 days: a new benchmark for quality care among children with sickle cell disease. Blood. 2007;11:3403a.
108. van Walraven C, Mamdani M, Fang J, Austin PC. Continuity of care and patient outcomes after hospital discharge. J Gen InternMed. 2004;19:624-31.
109. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003;138:161-167.
110. Cordeiro NJ, Oniyangi O. Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database Syst Rev. 2004:CD004448.
111. Brousseau DC, Scott JP, Hillery CA, Panepinto JA. The effect of magnesium on length of stay for pediatric sickle cell pain crisis. Acad EmergMed. 2004;11:968-972.
112. Benjamin LJ, Dampier CD, Jacox A, et al. Guideline for the Management of Acute and Chronic Pain in Sickle Cell Disease. In: American Pain Society Clinical Practice Guidelines Series No 1. Glenview, IL: American Pain Society; 1999.
113. Morgan MT. Use of meperidine as the analgesic of choice in treating pain from acute painful sickle cell crisis. Ann Emerg Med. 2008;51:202-203.
114. Howland MA, Goldfrank LR. Why meperidine should not make a comeback in treating patients with sickle cell disease. Ann EmergMed. 2008;51:203-205.
115. Ballas SK. Meperidine for acute sickle cell pain in the emergency department: revisited controversy. Ann Emerg Med. 2008;51:217.
116. Tobin DL, Holroyd KA, Reynolds RV, Wigal JK. The hierarchical factor structure of the coping strategies inventory. Cognitive Ther Res. 1989;13:343-361.
117. Zsebik G, O'Riordan MA, Berman B, Villela A. Low risk of meperidine-induced seizures in children with sickle cell disease [abstract]. Pediatr Blood Cancer. 2007;48:612.
118. Chulamokha L, Scholand SJ, Riggio JM, Ballas SK, Horn D, DeSimone JA. Bloodstream infections in hospitalized adults with sickle cell disease: a retrospective analysis. Am J Hematol. 2006;81:723-728.
119. Koppert W. Opioid-induced hyperalgesia-Pathophysiology and clinical relevance. Acute Pain. 2007;9:21-34.
120. Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005;49:902-908.
121. Graham AW, Schultz TK, Mayo-Smith MF, Ries RK. Principles of Addiction Medicine. 3rd ed. Chevy Chase, MD: American Society of AddictionMedicine; 2003.
122. Uhl GR, Sora I, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA. 1999;96:7752-7755.
123. Compton P, Geschwind DH, Alarcon M. Association between human mu-opioid receptor gene polymorphism, pain tolerance, and opioid addiction. AmJMed Genet B Neuropsychiatr Genet. 2003;121:76-82.
124. Klepstad P, Rakvag TT, Kaasa S, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48:1232-1239.
125. Mehta S, Kutlar F, Bailey L, et al. Mu opioid receptor 1 (MOR 1) polymorphisms among patients with sickle cell disease. Oral presentation. In: 27th Annual Meeting of the National Sickle Cell Disease Program. Los Angeles, CA; April 18-21, 2004.
126. Darbari DS, Minniti CP, Rana S, Van Den Anker J. Pharmacogenetics of morphine: potential implications in sickle cell disease. Am J Hematol. 2008;83:233-236.
127. Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, Van Den Anker J. UGT2B7 promoter variant-840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol. 2008;83:200-202.
128. Kopecky EA, Jacobson S, Joshi P, Koren G. Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clin Pharmacol Ther. 2004;75:140-146.
129. Buchanan ID, Woodward M, Reed GW. Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome. Pediatr Blood Cancer. 2005;45:716-724.
130. Weber ML, Hebbel RP, Gupta K. Morphine induces kidney injury in transgenic sickle cell mice. Blood. 2005;106: 884a-5a.
131. King T, Vardanyan A, Majuta L, et al. Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain. 2007;132:154-168.
132. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K. Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005;13:165-174.
133. Ferrante MF. Nonsteroidal anti-inflammatory drugs. In: Ferrante MF, Vade Bancoeur TR, eds. Post Operative Pain Management. New York: Churchill Livingstone; 1993a:133-143.
134. Perlin E, Finke H, Castro O, et al. Enhancement of pain control with ketorolac tromethamine in patients with sickle cell vaso-occlusive crisis. Am J Hematol. 1994;46:43-47.
135. Crain SM, Shen KF. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci USA. 1995;92:10540-10544.
136. Winkelmuller M, Winkelmuller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg. 1996;85:458-467.
137. Definitions Related to the Use of Opioids for the Treatment of Pain. American Academy of Pain Medicine American Pain Society American Academy of Addiction Medicine 2001. Available at http://www.ama-assn.org/ama1/pub/upload/mm/455/opioiddefinitions.pdf. Accessed March 31, 2008.
138. Benjamin LJ, Payne R. Pain in sickle cell disease: a multidimensional construct. In: Pace B, ed. Renaissance of Sickle Cell Disease Research in the Genomic Era. London: Imperial College Press; 2007:99-118.
139. Mercadante S, Ferrera P, Villari P, Arcuri E. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage. 2003;26:769-775.
140. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765-1769.
141. Gottschalk A, Smith DS. New concepts in acute pain therapy: preemptive analgesia. AmFamPhysician. 2001;63:1979-1984.
142. Baliki MN, Geha PY, Apkarian AV, Chialvo DR. Beyond feeling: chronic pain hurts the brain, disrupting the defaultmode network dynamics. J Neurosci. 2008;28:1398-1403.
143. Song I, Huganir RL. Regulation of AMPA receptors during synaptic plasticity. Trends Neurosci. 2002;25:578-588.
144. Carroll RC, Beattie EC, von Zastrow M, Malenka RC. Role of AMPA receptor endocytosis in synaptic plasticity. Nat Rev Neurosci. 2001;2:315-324.
145. Perez-Otano I, Ehlers MD. Homeostatic plasticity and NMDA receptor trafficking. Trends Neurosci. 2005;28:229-238.
146. Morishita W, Marie H, Malenka RC. Distinct triggering and expression mechanisms underlie LTD of AMPA and NMDA synaptic responses. Nat Neurosci. 2005;8:1043-1050.
147. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6:521-532.
148. Nakajima K, Kohsaka S. Microglia: activation and their significance in the central nervous system. J Biochem. 2001;130:169-175.
149. Deleo JA, Sorkin L, Watkins L, eds. Immune and Glial Regulation of Pain. Seattle: IASP Press; 2007.
150. Katz JL, Higgins ST. The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology. 2003;168:21-30.
151. Boyer EW, Shannon MT. The serotonin syndrome. N Engl J Med. 2005;352:1112-1120.
152. NIH. TheManagement of Sickle Cell Disease. National Heart, Lung and Blood Institute, No. 02-2117. 4th ed. Washington DC: National Institutes of Health; 2002.
153. Benjamin LJ, Dampier CD, Jacox A, et al. Guideline for the Management of Acute and Chronic Pain in Sickle-CellDisease. Glenview, IL: American Pain Society; 1999.
154. Sickle Cell Education Center. Georgia Comprehensive Sickle Cell Center, 2006. Available at www.scinfo.org. Accessed March 3, 2008.
155. Dunlop RJ, Bennett KC. Pain management for sickle cell disease. Cochrane Database Syst Rev. 2006:CD003350.
156. Gil KM, Carson JW, Sedway JA, Porter LS, Schaeffer JJ, Orringer E. Follow-up of coping skills training in adults with sickle cell disease: analysis of daily pain and coping practice diaries. Health Psychol. 2000;19:85-90.
157. Gil KM, Thompson RJ Jr, Keith BR, Tota-Faucette M, Noll S, Kinney TR. Sickle cell disease pain in children and adolescents: change in pain frequency and coping strategies over time. J Pediatr Psychol. 1993;18:621-637.
158. WHO Pain Ladder. World Health Organization, 2008. Available at http://www.who.int/cancer/palliative/painladder/en/. AccessedMarch 8, 2008.
159. Jacox A, Carr DB, Payne R. New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med. 1994;330:651-655.
160. Epstein K, Yuen E, Riggio JM, Ballas SK, Moleski SM. Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year study. J Natl Med Assoc. 2006;98:1109-1113.
161. Adewoye AH, Nolan V, McMahon L, Ma Q, Steinberg MH. Effectiveness of a dedicated day hospital for management of acute sickle cell pain. Haematologica. 2007;92:854-855.
162. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 2000;95:1130-1136.
163. The Georgia Comprehensive Sickle Cell Center at Grady Health System in Atlanta, Georgia: Center Description and Services. 2006. Available at http://www.scinfo.org/.
164. Wright J, Bareford D, Wright C, et al. Day case management of sickle pain: 3 years experience in a UK sickle cell unit. Br J Haematol. 2004;126:878-80.
165. Beyer J, Platt A, Kinney T. Assessment of Pain in Adults and Children with Sickle Cell Disease. Mt. Desert, ME: New England Regional Genetics Group; 1994.
166. Shapiro B, Schechter NL, Ohene-Frempong K. The Genetic Resource, Sickle Cell Related Pain: Assessment and Management. Mt. Desert, ME: New England Regional Genetics Group; 1994.
167. Frei-Jones MJ, Baxter AL, Rogers ZR, Buchanan GR. Vasoocclusive episodes in older children with sickle cell disease: emergency department management and pain assessment. J Pediatr. 2008;152:281-285.
168. Ballas SK. Current issues in sickle cell pain and its management. Hematology AmSoc Hematol Educ Program. 2007; 110: 97-105.
169. Tanabe P, Myers R, Zosel A, et al. Emergency department management of acute pain episodes in sickle cell disease. Acad EmergMed. 2007;14:419-425.
170. Pain Episodes. Georgia Comprehensive Sickle Cell Center, 2006. Accessed at http://www.scinfo.org/painepi.htm.
171. The Georgia Comprehensive Sickle Cell Center at Grady Health System in Atlanta, Georgia 2006. (Accessed 2008)
172. Payne R. Pain management is sickle cell disease: rationale and techniques. Ann NY Acad Sci. 1989;565:189-206.
173. Platt A, Eckman JR, Beasley J, Miller G. Treating sickle cell pain: an update from the Georgia comprehensive sickle cell center. J Emerg Nurs. 2002;28:297-303.
174. Gonzalez ER, Bahal N, Hansen LA, et al. Intermittent injection vs patient-controlled analgesia for sickle cell crisis pain. Comparison in patients in the emergency department. Arch InternMed. 1991;151:1373-1378.
175. Holbrook CT. Patient-controlled analgesia pain management for children with sickle cell disease. J Assoc Acad Minor Phys. 1990;1:93-96.
176. Melzer-Lange MD, Walsh-Kelly CM, Lea G, Hillery CA, Scott JP. Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department. Pediatr Emerg Care. 2004;20:2-4.
177. Trentadue NO, Kachoyeanos MK, Lea G. A comparison of two regimens of patient-controlled analgesia for children with sickle cell disease. J Pediatr Nurs. 1998;13:15-9.
178. van Beers EJ, van Tuijn CF, Nieuwkerk PT, Friederich PW, Vranken JH, Biemond BJ. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol. 2007;82:955-60.
179. Schechter NL, Berrien FB, Katz SM. PCA for adolescents in sickle-cell crisis. Am J Nurs. 1988;88:719, 21-2.
180. Schechter NL, Berrien FB, Katz SM. The use of patientcontrolled analgesia in adolescents with sickle cell pain crisis: a preliminary report. J Pain Symptom Manage. 1988;3:109-113.
181. Ballas SK. Ethical issues in the management of sickle cell pain. Am J Hematol. 2001;68:127-132.
182. Elander J, Lusher J, Bevan D, Telfer P, Burton B. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain SymptomManage. 2004;27:156-169.
183. Elander J, Marczewska M, Amos R, Thomas A, Tangayi S. Factors affecting hospital staff judgments about sickle cell disease pain. J BehavMed. 2006;29:203-214.
184. Elander J, Midence K. A review of evidence about factors affecting quality of pain management in sickle cell disease. Clin J Pain. 1996;12:180-193.
185. Armstrong FD, Pegelow CH, Gonzalez JC, Martinez A. Impact of children's sickle cell history on nurse and physician ratings of pain and medication decisions. J Pediatr Psychol. 1992;17:651-164.
186. Todd KH, Green C, Bonham VL, Jr., Haywood C, Jr., Ivy E. Sickle cell disease related pain: crisis and conflict. J Pain 2006;7:453-458.
187. Ballas SK. Current issues in sickle cell pain and its management. Hematology Am Soc Hematol Educ Program. 2007;2007:97-105.
188. Quill TE. Partnerships in patient care: a contractual approach. Ann InternMed. 1983;98:228-234.
189. Donovan MI, Evers K, Jacobs P, Mandleblatt S. When there is no benchmark: designing a primary care-based chronic pain management program from the scientific basis up. J Pain SymptomManage. 1999;18:38-48.
190. Gil KM, Carson JW, Porter LS, et al.Daily stress and mood and their association with pain, health-care use, and school activity in adolescents with sickle cell disease. J Pediatr Psychol. 2003;28:363-373.
191. Smith WR, Bovbjerg VE, Penberthy LT, et al. Understanding pain and improving management of sickle cell disease: the PiSCES study. J NatlMed Assoc. 2005;97:183-93.
192. Ennis JT, Serjeant GR, Middlemiss H. Homozygous sickle cell disease in Jamaica. Br J Radiol. 1973;46:943-950.
193. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325:1476-1481.
194. Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Rel Res. 1993:136-143.
195. Riggs W Jr, Rockett JF. Roentgen chest findings in childhood sickle cell anemia. A new vertebral body finding. Am J Roentgenol Radium Ther NuclMed. 1968;104:838-845.
196. Diggs LW. Bone and joint lesions in sickle-cell disease. Clin Orthop Rel Res. 1967;52:119-143.
197. Diggs LW, ed. Anatomic Lesions in Sickle Cell Anemia. St. Louis: C.V.Mosby Co; 1973.
198. Neumayr LD, Aguilar C, Earles AN, et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am. 2006;88:2573-2582.
199. Hernigou P, Habibi A, Bachir D, Galacteros F. The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J Bone Joint Surg Am. 2006;88:2565-2572.
200. Bishop AR, Roberson JR, Eckman JR, Fleming LL. Total hip arthroplasty in patients who have sickle-cell hemoglobinopathy. J Bone Joint Surg Am. 1988;70:853-855.
201. Hernigou P, Zilber S, Filippini P, Mathieu G, Poignard A, Galacteros F. Total THA in adult osteonecrosis related to sickle cell disease. Clin Orthop Rel Res. 2008;466:300-308.
202. Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood. 1989;74:1403-1408.
203. Serjeant GR. Leg ulceration in sickle cell anemia. Arch Intern Med. 1974;133:690-694.
204. Eckman JR. Leg ulcers in sickle cell disease. Hematol Oncol Clin North Am. 1996;10:1333-1344.
205. Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin North Am. 2005;19:785-802.
206. Adams RJ. Neurologic complications. In: Embury SH, Hebbel RP, Mohondas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. 1st ed. NewYork: Raven Press; 1994:599-621.
207. Konotey-Ahulu FI.Mental-nerve neuropathy: a complication of sickle-cell crisis. Lancet. 1972;2:388.
208. Asher SW. Multiple cranial neuropathies, trigeminal neuralgia, and vascular headaches in sickle cell disease, a possible common mechanism. Neurology. 1980;30:210-211.
209. Sommer C. Painful neuropathies. Curr Opin Neurol. 2003;16: 623-628.
210. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353: 1959-1964.
211. Harden RN. Chronic neuropathic pain.Mechanisms, diagnosis, and treatment. Neurologist. 2005;11:111-122.
212. Irving GA. Contemporary assessment and management of neuropathic pain. Neurology. 2005;64:S21-27.
213. Siddall PJ, Cousins MJ. Persistent pain as a disease entity: implications for clinical management. Anesth Analg. 2004;99: 510-520.
214. Edwards RR. Individual differences in endogenous pain modulation as a risk factor for chronic pain. Neurology. 2005;65: 437-443.
215. Krantz MJ, Mehler PS. Treating opioid dependence. Growing implications for primary care. Arch Intern Med. 2004;164: 277-288.
216. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25:171-186.
217. Schofferman J. Long-term use of opioid analgesics for the treatment of chronic pain of nonmalignant origin. J Pain SymptomManage. 1993;8:279-288.
218. Ballantyne JC, Mao J. Opioid therapy for chronic pain.NEngl J Med. 2003;349:1943-1953.
219. Ballantyne JC. Opioids for chronic pain: taking stock. Pain. 2006;125:3-4.
220. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372-380.
221. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006;125:172-179.
222. Medicine AAoP, Society AP. The use of opioids for the treatment of chronic pain: a consensus statement. Clin J Pain. 1997;13:6-8.
223. Fishman SM, Wilsey B, Yang J, Reisfield GM, Bandman TB, Borsook D. Adherence monitoring and drug surveillance in chronic opioid therapy. J Pain Symptom Manage. 2000;20:293-307.
224. States Federation of Medical Boards, Model policy for the use of controlled substances for the treatment of pain. Available at: http://www.fsmb.org/pdf/2004 grpol Controlled Substances.pdf. 2004.
225. Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the management of chronic pain. J Pain SymptomManage. 1999;18:27-37.
226. Consent for chronic opioid therapy. American Academy of Pain Medicine, 2001. Available at: http://www.painmed. org/pdf/opioid consent form.pdf.
227. Long-term Controlled Substances Therapy for Chronic Pain. Sample Agreement. 1997 Available at: http://www.painmed. org/pdf/controlled substances sample agrmt.pdf.
228. Arnold RM, Han PK, Seltzer D. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am JMed. 2006;119:292-296.
229. Hariharan J, Lamb GC, Neuner JM. Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med. 2007;22:485-490.
230. Zylicz Z, Twycross R. Opioid-induced hyperalgesia may be more frequent than previously thought. J Clin Oncol. 2008;26:1564.
231. Doverty M, White JM, Somogyi AA, Bochner F, Ali R, Ling W. Hyperalgesic responses in methadone maintenance patients. Pain. 2001;90:91-96.
232. White JM. Pleasure into pain: the consequences of long-term opioid use. Addict Behav. 2004;29:1311-1324.
233. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104:570-587.
234. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am. 2007;91:199-211.
235. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002;100:213-217.
236. Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep. 2006;10:67-70.
237. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised. 4th ed. Washington, DC: American Psychiatric Association; 1994.
238. Kalivas PW, O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology. 2008;33: 166-180.
239. O'Brien CP. Research advances in the understanding and treatment of addiction. AmJ Addict. 2003;12 Suppl 2:S36-47.
240. Jackson JL, Kroenke K. Difficult patient encounters in the ambulatory clinic: clinical predictors and outcomes. Arch InternMed. 1999;159:1069-1075.
241. Adams J, Murray R, 3rd. The general approach to the difficult patient. EmergMed Clin North Am. 1998;16:689-700.
242. Hull SK, Broquet K. How to manage difficult patient encounters. Fam Pract Manage. 2007;14:30-34.
243. Krebs EE, Garrett JM, Konrad TR. The difficult doctor? Characteristics of physicians who report frustration with patients: an analysis of survey data. BMC Health Serv Res. 2006;6: 128.
244. Koekkoek B, van Meijel B, Hutschemaekers G. "Difficult patients" in mental health care: a review. Psychiatr Serv. 2006;57:795-802.
245. Haas LJ, Leiser JP, Magill MK, Sanyer ON.Management of the difficult patient. AmFamPhysician. 2005;72:2063-2068.
246. Tandeter H. Making peace with your "difficult patient." Patient Educ Couns. 2006;62:3-4.
247. Elder N, Ricer R, Tobias B. How respected family physicians manage difficult patient encounters. J Am Board Fam Med. 2006;19:533-541.
248. Marks RM, Sachar EJ. Undertreatment of medical inpatients with narcotic analgesics. Ann InternMed. 1973;78:173-181.
249. Marlowe KF, Chicella MF. Treatment of sickle cell pain. Pharmacotherapy. 2002;22:484-491.
250. Sutton M, Atweh GF, Cashman TD, DavisWT. Resolving conflicts: misconceptions and myths in the care of the patient with sickle cell disease. Mt Sinai JMed. 1999;66:282-285.
251. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. NEngl J Med. 2008;358:1362-1369.
252. Eccleston C, Yorke L, Morley S, Williams AC, Mastroyannopoulou K. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2003:CD003968.
253. Anie KA, Green J. Psychological therapies for sickle cell disease and pain. Cochrane Database Syst Rev. 2002: CD001916.
254. Ballas SK. Sickle cell disease: current clinical management. Semin Hematol. 2001;38:307-314.